Cognitive therapy for multiple sclerosis: A preliminary study

Alternative Therapies in Health and Medicine

Volumn 2, Issue 5, 1996, Pages 70-74

  Rodgers, Denise ^a   Khoo, Keith ^c   MacEachen, Mary ^a   Oven, Mia ^c   Beatty, William W ^b  

^a Assoc Devmt of Mind/Body Potential   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COGNITIVE THERAPY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

ADULT; AGED; COGNITIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0030240564     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31:331-336.
2. Mitchell JN. Multiple sclerosis and the prospects for employment. J Soc Occup Med. 1981;31:134-138.
3. Gronning M, Hannisdal E, Mellgren SV. Multivariate analysis of factors associated with unemployment in people with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1990;53:388-390.
4. Kornblith AB, La Rocca NG, Baum HM. Employment in individuals with multiple sclerosis. Int J Rehabil Res. 1986;9:155-165.
5. IFBN Multiple Sclerosis Study Group. Interferon beta-1B is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
6. Paty DW, Li DKB, UBC MS/MRI Study Group IFNB MS Study Group. Interferon beta-1B is effective in relapsing-remitting multiple sclerosis. II. MRI analysis of results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
7. Duquette P, Despault L, Knobler RL, et al. Interferon beta-1B in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
8. Pliskin NH, Towle VL, Hamer DP, et al. The effects of interferon-beta on cognitive function in multiple sclerosis. Ann Neurol. 1994;36:326. Abstract.
9. Goodkin DE, Rudick RA, Vanderbrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37:30-40.
10. Fischer J, Goodkin DE, Rudick RA, et al. Low-dose (7.5 mg) oral methotrexate improves neuropsychological function in patients with chronic progressive multiple sclerosis. Ann Neurol. 1994;36:289. Abstract.
11. Sipe J, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994;344:9-13.
12. Warren S. The role of stress in multiple sclerosis. In: Rao SM, ed. Neurobehavioral Aspects of Multiple Sclerosis. New York, NY: Oxford; 1990:196-209.
13. Derogatis LR, Abeloft MD, Melisaratos N. Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA. 1979;242:1504-1508.
14. Ragland DR, Brand RJ. Type A behavior and mortality from coronary heart disease. N Engl J Med. 1988;318:65-69.
15. Dean C, Surfees PG. Do psychological factors predict survival in breast cancer? J Psychosom Res. 1988;33:561-569.
16. Casselith BR, Lask EJ, Miller DS, Brown LE, Miller C. Psychosocial correlates of survival in advanced malignant disease? N Engl J Med. 1985;312:1551-1555.
17. Jamison RN, Burish TG, Wallston KA. Psychogenic factors in predicting survival of breast cancer patients. J Clin Oncol. 1987;5:768-772.
18. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Survival in amyotrophic lateral sclerosis: the role of psychological factors. Arch Neurol. 1994;51:17-23.
19. Honig LS. Survival in amyotrophic lateral sclerosis. Arch Neurol. 1995;5:126. Abstract.
20. McDonald ER, Hillel A. Survival in amyotrophic lateral sclerosis. Arch Neurol. 1995;52:126-127.
21. Allen DX, Landis RKB, Schramke CJ. The role of psychologists in the treatment of multiple sclerosis. Int J Rehabil Health. 1995;1:97-123.
22. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
23. Smith AA. Symbol Digit Modalities Test. Manual. Los Angeles, Calif: Western Psychological Services; 1982.
24. Zachary RA. Shipley Institute of Living Scale. Revised Manual. Los Angeles, Calif: Western Psychological Services; 1986.
25. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
26. Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology. 1995;45:718-723.
27. Semmes-Weinstein Pressure Aesthesiometer. Manual. Menominee Falls, Wis: Smith & Nephew Rolyan.
28. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.